Rapid LC-ESI-MS-MS method for the simultaneous determination of clopidogrel and its carboxylic acid metabolite in human plasma

Journal of Chromatographic Science

Volumn 46, Issue 10, 2008, Pages 867-875

  Patel, Nitesh K ^a,b   Subbaiah, Gunta ^b   Shah, Hiten ^b   Kundlik, Mohan ^b   Shrivastav, Pranav S ^a  

^a GUJARAT UNIVERSITY   (India)

^b Torrent Research Center   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 56549114841     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/46.10.867     Document Type: Article

References (20)

1. T. Richter, T.E. Murdter, G. Heinkele, J. Pleiss, S. Tatzel, M. Schwab, M. Eichelbaum, and U.M. Zanger. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J. Pharm. Exp. Ther. 308: 189-97 (2004).
2. P. Savi and J.M. Herbert. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin. Thromb. Hemost. 31(2): 174-83 (2005).
3. J.M. Pereillo, M. Maftouh, A. Andrieu, M.F. Uzabiaga, O. Fedeli, P. Savi, M. Pascal, J.M. Herbert, J.P. Maffrand, and C. Picard. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Met. Disp. 30(11): 1288-95 (2002).
4. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 348: 1329-39 (1996).
5. P. Savi, J.M. Herbert, A.M. Pflieger, F. Dol, D. Delebassee, J. Combalbert, G. Defreyn, and J.P. Maffrand. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem. Pharmacol. 44: 527-32 (1992).
6. M. Reist, M. Roy-De Vos, J.P. Montseny, J.M. Mayer, P.A. Carrupt, Y. Berger, and B. Testa. Very slow chiral inversion of clopidogrel in rats: A pharmacokinetic and mechanistic investigation. Drug Metab. Dispos. 28(12): 1405-10 (2000).
7. M.C. Guillin, G. Bonnet, J. Sissmann, J. Necciari, and J.P. Dickinson. Pharmacodynamics and pharmacokinetics of the novel antiplatelet agent, clopidogrel, in the young and the elderly with and without symptomatic atherosclerosis. Eur. Heart J. 17(Suppl): 161 (1996).
8. P. Lagorce, Y. Perez, J. Ortiz, J. Necciari, and F. Bressolle. Assay method for the carboxylic acid metabolite of clopidogrel in human plasma by gas chromatography-mass spectrometry. J. Chromatogr. B 720(1-2): 107-17 (1998).
9. H. Caplain, M.D. Francois, C. Gaud, and J. Necciari. Pharmacokinetics of clopidogrel. Semin. Thromb. Hemost. 25(2): 25-8 (1999).
10. S.S. Singh, K. Sharma, D. Barot, P.R. Mohan, and V.B. Lohray. Estimation of carboxylic acid metabolite of clopidogrel in Wistar rat plasma by HPLC and its application to a pharmacokinetic study. J. Chromatogr. B 821(2): 173-80 (2005).
11. E. Souri, H. Jalalizadeh, A. Kebriaee-Zadeh, M. Shekarchi, and A. Dalvandi. Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study. Biomed. Chromatogr. 20(12): 1309-14 (2006).
12. H. Ksycinska, P. Rudzki, and M. Bukowska-Kiliszek. Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS. J. Pharm. Biomed. Anal. 41(2): 533-9 (2006).
13. A. Mitakos and I. Panderi. Determination of the carboxylic acid metabolite of clopidogrel in human plasma by liquid chromatography-electrospray ionization mass spectrometry. Anal. Chim. Acta 505(1): 107-14 (2004).
14. A. Lainesse, Y. Ozalp, H. Wong, and R.S. Alpan. Bioequivalence study of clopidogrel bisulfate film-coated tablets Arzneimittelforschung 54(9a): 600-4 (2004).
15. R.V. Nigori, V.N. Kandikere, M. Shukla, K. Mudigonda, S. Maurya, and R. Boosi. Quantification of clopidogrel in human plasma by sensitive liquid chromatography-tandem mass spectrometry. Rapid Commun. Mass Spectrom. 20(11): 1695-700 (2006).
16. A. Robinson, J. Hillis, C. Neal, and A.C. Leary. The validation of a bioanalytical method for the determination of clopidogrel in human plasma. J. Chromatogr. B 848(2): 344-54 (2007).
17. B.S. Shin and S.D. Yoo. Determination of clopidogrel in human plasma by liquid chromatography-tandem mass spectrometry: application to a clinical pharmacokinetic study. Biomed. Chromatogr., in press.
18. D. Taubert, A. Kastrati, S. Harlfinger, O. Gorchakova, A. Lazar, N.V. Beckerath, A. Schomig, and E. Schomig. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb. Haemost. 92(2): 311-316 (2004).
19. Guidance for Industry: Bioanalytical method validation, U.S. Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM), May 2001.
20. Guidance for Industry: ICH E6 Good Clinical Practice, U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Centre for Biologics Evaluation and Research (CBER), April 1996.